About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT03799172

Echinocandins Versus Azoles for Candidemia Treatment

Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. ...

Lead sponsor: Hospices Civils de Lyon•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Hospices Civils de Lyon

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients who had a diagnosis of candidemia during ICU stay and were treated with echinocandins or azoles

Exclusion Criteria

•Patients with neutropenia
•Patients without antifungal treatment
•Patients who received antifungal therapy for more than two days before candidemia diagnosis
•Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy
•Patients who received less than 4 days of antifungal therapy after candidemia diagnosis

Related studies

RECRUITINGPhase 3

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858 · Candidemia, Candidiasis, Invasive

COMPLETEDPhase 3

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT04368559 · Candidemia, Mycoses, and more

TERMINATEDPhase 3

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862 · Candidiasis, Invasive, Candidemia

Not Yet RecruitingPhase 3

A Randomized Study of a Short Duration Therapy for Candidemia

NCT06859671 · CANDIDEMIA

COMPLETEDPhase 3

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

NCT03363841 · Candidiasis, Invasive, Candidemia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 4, 2020Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment79

Start dateNov 2018

Last updatedMar 4, 2020

Condition

Locations shown

Hospices Civils de Lyon, Hôpital de la Croix-Rousse

Lyon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2020Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions